This company has been acquired
CVET Stock Overview
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Covetrus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.99 |
| 52 Week High | US$21.20 |
| 52 Week Low | US$13.39 |
| Beta | 1.51 |
| 1 Month Change | 0.53% |
| 3 Month Change | 0.91% |
| 1 Year Change | 5.58% |
| 3 Year Change | 107.00% |
| 5 Year Change | n/a |
| Change since IPO | -50.02% |
Recent News & Updates
Recent updates
Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line
Aug 04Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders
Jun 02Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price
May 02
Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?
Jan 07We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Oct 21An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued
Sep 16Estimating The Intrinsic Value Of Covetrus, Inc. (NASDAQ:CVET)
May 31Covetrus, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Is Covetrus (NASDAQ:CVET) Using Too Much Debt?
May 05Covetrus, Inc.: Well Positioned To Enjoy Market Crosscurrents
Apr 30Who Has Been Selling Covetrus, Inc. (NASDAQ:CVET) Shares?
Feb 26We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Jan 22Covetrus reports Q4 net sales of prescription management business
Jan 13Covetrus (NASDAQ:CVET) Shareholders Have Enjoyed An Impressive 106% Share Price Gain
Dec 18
Covetrus, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 12Covetrus Q3 2020 Earnings Preview
Nov 09Shareholder Returns
| CVET | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.5% | 2.5% | 2.7% |
| 1Y | 5.6% | 3.5% | 26.0% |
Return vs Industry: CVET matched the US Healthcare industry which returned 4.9% over the past year.
Return vs Market: CVET exceeded the US Market which returned -25.8% over the past year.
Price Volatility
| CVET volatility | |
|---|---|
| CVET Average Weekly Movement | 0.3% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CVET has not had significant price volatility in the past 3 months.
Volatility Over Time: CVET's weekly volatility has decreased from 6% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 4,873 | Ben Wolin | www.covetrus.com |
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners.
Covetrus, Inc. Fundamentals Summary
| CVET fundamental statistics | |
|---|---|
| Market cap | US$2.94b |
| Earnings (TTM) | -US$13.00m |
| Revenue (TTM) | US$4.65b |
0.6x
P/S Ratio-226.3x
P/E RatioIs CVET overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVET income statement (TTM) | |
|---|---|
| Revenue | US$4.65b |
| Cost of Revenue | US$3.77b |
| Gross Profit | US$882.00m |
| Other Expenses | US$895.00m |
| Earnings | -US$13.00m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.093 |
| Gross Margin | 18.97% |
| Net Profit Margin | -0.28% |
| Debt/Equity Ratio | 68.7% |
How did CVET perform over the long term?
See historical performance and comparison